The GLP is committed to full transparency. Download and review our Annual Report.

Can money cure cancer?

| | April 15, 2016

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion and analysis.

Tech entrepreneur Sean Parker is just the latest big name to put up big money to fight cancer.

Parker, who helped found Facebook and Napster, plans to spend $250 million to build teams of researchers who aim to harness the immune system to attack cancer.

So, will all that effort amount to anything?

They say they’re supporting a new model of cancer research and they use a lot of MBA buzzwords to make that point: They talk about smashing silos, crunching data, and emphasizing translational research that moves discoveries from the lab bench to patients, not just curing a bunch of lab mice. Above all, they emphasize the power of collaboration.

At a launch event in Los  Angeles, Parker said the idea was to develop a “shared roadmap for the field” so that once the Parker Institute’s partners identify a research priority “we fund it and we go big.”

Some battle-scarred veterans of the country’s previous wars on cancer are holding their applause.

Much of the new funding from private sources springs from a concern that federal agencies fund mostly cautious, incremental research, producing cool findings about basic cancer biology but not many drugs that make a meaningful difference to patients.

Read full, original post: Sean Parker’s put up big bucks for cancer. We’ve got questions

The GLP aggregated and excerpted this article to reflect the diversity of news, opinion, and analysis. Click the link above to read the full, original article.
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend